

Presentations at 2025 ESMO Congress

October 17–21, 2025 (All times CEST)

PRESENTATION	NAME	SESSION/LOCATION/TIME
--------------	------	-----------------------

Friday, October 17, 2025

LBA77 - FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC

Pasi A. Jänne, MD, MPH
Presenting Author

Proffered paper session:
NSCLC metastatic
Berlin Auditorium-
Hub 27
5:00-5:10

Saturday, October 18, 2025

Adverse events with ADCs

Paolo Tarantino, MD

Young Oncologist Session:
Young Oncologists clinical case
discussions
Erfurt Auditorium-
CityCube A
9:00-10:00

LBA16- Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2- aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERA BC trial

Erica Mayer, MD, MPH
Presenting Author

Proffered paper session 1:
Breast cancer, metastatic
Berlin Auditorium-
Hub 27
10:15-10:25

Preventing and treating resistance

Pasi A. Jänne, MD, MPH

Education Session:
Targeting oncogenes in NSCLC
Munich Auditorium-
CityCube B
10:40-11:05

2758MO- Updated results from a phase 1/2 study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers

Himisha Beltran, MD
Presenting Author

Mini Oral session 1:
Non-metastatic NSCLC
Hamburg Auditorium-
CityCube A
4:35-4:40

Presentations at 2025 ESMO Congress

October 17–21, 2025 (All times CEST)

PRESENTATION	NAME	SESSION/LOCATION/TIME
Sunday, October 19, 2025		
2594MO - Association of circulating kidney injury molecule-1 (KIM-1) levels with clinical outcomes in advanced renal cell carcinoma (aRCC): Retrospective analysis of COSMIC-313	Wenxin (Vincent) Xu, MD Presenting Author	Mini Oral session 2: GU tumours, renal & urothelial Bonn Auditorium- Hall 7.1c 8:35-8:40
Optimising the safety of ADCs	Paolo Tarantino, MD	Education Session: The next frontier of antibody-drug conjugate development Nuremberg Auditorium- Hall 5.2 8:50-9:10
LBA20 - Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)	Sara Tolaney, MD, MPH Senior Author	Proffered paper session 2: Breast cancer, metastatic Munich Auditorium- CityCube B 9:15-9:25
2599MO - Soluble MAdCAM-1 predicts outcomes in patients with metastatic renal cell carcinoma: results from three independent clinical trials	Marc Machaalani, MD Presenting Author	Mini Oral session 2: GU tumours, renal & urothelial Bonn Auditorium- Hall 7.1c 9:40-9:45
LBA86 - Randomised phase 3 trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)	Paul Nguyen, MD, MBA Presenting Author (Dana-Farber Brigam Cancer Center)	Proffered paper session: GU tumours, prostate, penile and testis Hamburg Auditorium- CityCube A 10:15-10:25
GLP-1 receptor agonists and cancer risk	Erica Pimenta, MD, PhD	Special Session: Opportunities for targeting Glucagon Like Peptide-1 (GLP-1) in cancer prevention and treatment Heidelberg Auditorium- Hall 6.2 10:35-10:55

Presentations at 2025 ESMO Congress

October 17–21, 2025 (All times CEST)

PRESENTATION	NAME	SESSION/LOCATION/TIME
Sunday, October 19, 2025		
Therapeutic cancer vaccines: Clinical perspectives	Catherine Wu, MD	Keynote Lecture: Therapeutic cancer vaccines/Munich Auditorium- CityCube B/12:05-12:30
Combinations with ADCs	Joaquim Bellmunt, MD, PhD	Education Session: Understanding MOA, efficacy and toxicity of ADCs in bladder cancer Nuremberg Auditorium- Hall 5.2 3:25-3:45
1325MO - Retifanlimab (Anti-PD-1 mAb) Alone Or In Combination With Anti-LAG3 ± Anti-TIM3 mAbs In Previously Untreated, Recurrent And/ Or Metastatic (R/M) PD-L1+ HNSCC: A Double-Blind Randomised Controlled Phase 2 Trial Inflammatory disease	Robert Haddad, MD Presenting Author	Mini oral session: Head & neck cancer Cologne Auditorium- CityCube A 4:40-4:45
Inflammatory disease	Filipa Lynce, MD	Education Session: Tailoring breast cancer care for special populations Hamburg Auditorium- CityCube A 4:50-5:10

Presentations at 2025 ESMO Congress

October 17–21, 2025 (All times CEST)

PRESENTATION	NAME	SESSION/LOCATION/TIME
--------------	------	-----------------------

Monday, October 20, 2025

2277MO - Magnitude of Clinical Benefit of Cancer Medicines in Curative Setting and Health Technology Assessment Decisions in Europe	Thomas Hwang, MD Presenting Author (Dana-Farber Brigham Cancer Center)	Mini Oral session 2: Policy Bochum Auditorium- Hall 6.1 10:20-10:25
--	---	--

486MO - Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC)	Erica Mayer, MD, MPH Presenting Author	Mini oral session: Breast cancer, metastatic Munich Auditorium- CityCube B 10:25-10:30
--	---	---

Blurring the definition of lung cancer resectability in the era of highly effective neoadjuvant therapies	Paula Ugalde, MD (Dana-Farber Brigham Cancer Center)	Challenge Your Expert Heidelberg Auditorium- Hall 6.2 10:30-10:50
---	--	--

Mutation detection and monitoring	Matthew Freedman, MD	Special Session: Circulating tumor DNA Bonn Auditorium- Hall 7.1c 12:30-12:45
-----------------------------------	----------------------	--

LBA8 - IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer	Joaquim Bellmunt, MD, PhD Co-Senior Author	Presidential Symposium 3: Berlin Auditorium- Hub 27 4:30-4:42
---	---	---

3136O - AI-Generated Synthetic Cohorts for Accelerated Clinical Trial Design and Collaboration: Data from 19,000 Patients (Pts) with Metastatic Breast Cancer (MBC)	Eddy Saad, MD, MSc Presenting Author	Proffered paper session: AI & digital oncology Munich Auditorium- CityCube B 5:20-5:30
--	---	---

CART-T and CNS lymphoma	Lakshmi Nayak, MD	Education Session: Primary CNS lymphoma Koblenz Auditorium- Hall 5.2 5:30-5:50
-------------------------	-------------------	---